Skip to content

Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib?

Document Type
Publications · Journal Article
Registered DB
SCIEScopus
Journal Ranking
JCR Q3
Journal
LEUKEMIA RESEARCH33(11) · pp.1459 · 2009
Citation
Web of Science 5
JCR IF
JCR 2008 2.39
ISSN
0145-2126

Authors

  1. Song, Moo-KonFirst authorDepartment of Hematology-Oncology, Pusan National University Hospital Medical Research Institute, South Korea
  2. Chung, Joo SeopCorresponding authorDepartment of Hematology-Oncology, Pusan National University Hospital Medical Research Institute, South Korea
  3. Seol, Young-miDepartment of Hematology-Oncology, Pusan National University Hospital Medical Research Institute, South Korea
  4. Kim, Seung-GeunDepartment of Hematology-Oncology, Pusan National University Hospital Medical Research Institute, South Korea
  5. Shin, Ho-JinDepartment of Hematology-Oncology, Pusan National University Hospital Medical Research Institute, South Korea
  6. Choi, Young-jinDepartment of Hematology-Oncology, Pusan National University Hospital Medical Research Institute, South Korea
  7. Cho, Goon JaeDepartment of Hematology-Oncology, Pusan National University Hospital Medical Research Institute, South Korea

Abstract

imatinib-induced macrocytic anemia was known to result from c-kit inhibition in chronic myeloid leukemia (CML). However, recent studies showed that the prevalence of anemia is increased with high trough imatinib level and increased doses of imatinib influence decreased proliferation of burst forming units-erythroids (BFU-Es). The aim of this study was to evaluate the continuously increased mean cell volume (MCV) level's correlation with cytogenetic response and the favorable outcome in early chronic phase (CP)-CML patients. Clinical importance of MCV level was evaluated to correlate with cytogenetic response and compared with Sokal score, a known excellent prognostic parameter of cytogenetic response (CCR) in 84 early CP-CML patients. The patients with early and continuously increased MCV level irrespective of anemia achieved higher CCR after 12 months of imatinib therapy than patients with non-CCR (p = 0.011). When the value was compared with low Sokal score, elevated MCV was independent predictor of CCR (RR = 12.925, p = 0.002 vs. RR = 35.445, p < 0.001). Furthermore, the patients with early and continuously increased MCV level had a higher probability of maintaining CCR than non-increased level (p = 0.019). Increased MCV level was surrogate marker of achievement and durability to CCR for early CP-CML patients in the present study. (C) 2009 Elsevier Ltd. All rights reserved.

Keywords

ImatinibChronic myelogenous leukemiaMean cell volumeCytogenetic responseSokal scoreCHRONIC MYELOGENOUS LEUKEMIACHRONIC-PHASEDOSE-ESCALATIONTHERAPYMESYLATERESISTANCEOVERCOMEFAILURECML

Identifiers

WoS UID
000269870400007